Haemonetics Stock Analysis
| HAE Stock | USD 82.11 2.13 2.66% |
Haemonetics holds a debt-to-equity ratio of 1.123. Haemonetics' financial risk is the risk to Haemonetics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Haemonetics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Haemonetics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Haemonetics Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Haemonetics' stakeholders.
For most companies, including Haemonetics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Haemonetics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Haemonetics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Haemonetics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Haemonetics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Haemonetics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Haemonetics is said to be less leveraged. If creditors hold a majority of Haemonetics' assets, the Company is said to be highly leveraged.
Haemonetics is overvalued with Real Value of 74.14 and Hype Value of 80.38. The main objective of Haemonetics stock analysis is to determine its intrinsic value, which is an estimate of what Haemonetics is worth, separate from its market price. There are two main types of Haemonetics' stock analysis: fundamental analysis and technical analysis.
The Haemonetics stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Haemonetics' ongoing operational relationships across important fundamental and technical indicators.
Haemonetics | Build AI portfolio with Haemonetics Stock |
Haemonetics Stock Analysis Notes
About 99.0% of the company shares are owned by institutional investors. The book value of Haemonetics was currently reported as 18.17. The company has Price/Earnings To Growth (PEG) ratio of 1.22. Haemonetics had not issued any dividends in recent years. The entity had 2:1 split on the 3rd of December 2012. Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 2821 people. To learn more about Haemonetics call Ronald Gelbman at 781 848 7100 or check out https://www.haemonetics.com.Haemonetics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Haemonetics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Haemonetics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Haemonetics appears to be risky and price may revert if volatility continues | |
| Haemonetics has a strong financial position based on the latest SEC filings | |
| Over 99.0% of the company shares are owned by institutional investors |
Haemonetics Upcoming and Recent Events
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 9th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Haemonetics Thematic Classifications
In addition to having Haemonetics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Baby Boomer ProspectsMega stocks, funds and ETFs that tend to appeal to people considering retirement from the work force | |
 | Obamacare RepealLarge healthcare related equities associated with Obamacare |
Haemonetics Market Capitalization
The company currently falls under 'Mid-Cap' category with a total capitalization of 3.85 B.Haemonetics Profitablity
The company has Net Profit Margin of 0.13 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.21 %, which entails that for every 100 dollars of revenue, it generated $0.21 of operating income.Technical Drivers
As of the 5th of January, Haemonetics retains the Downside Deviation of 1.6, market risk adjusted performance of 6.9, and Risk Adjusted Performance of 0.1577. Haemonetics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Haemonetics information ratio, value at risk, and the relationship between the standard deviation and treynor ratio to decide if Haemonetics is priced fairly, providing market reflects its last-minute price of 82.11 per share. Given that Haemonetics has jensen alpha of 0.8731, we strongly advise you to confirm Haemonetics's regular market performance to make sure the company can sustain itself at a future point.Haemonetics Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Simple Moving Average indicator is calculated by adding the closing price of Haemonetics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Haemonetics short-term fluctuations and highlight longer-term trends or cycles.
Haemonetics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Haemonetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Haemonetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Haemonetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Haemonetics Outstanding Bonds
Haemonetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Haemonetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Haemonetics bonds can be classified according to their maturity, which is the date when Haemonetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Haemonetics Predictive Daily Indicators
Haemonetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Haemonetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Haemonetics Forecast Models
Haemonetics' time-series forecasting models are one of many Haemonetics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Haemonetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Haemonetics Bond Ratings
Haemonetics financial ratings play a critical role in determining how much Haemonetics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Haemonetics' borrowing costs.| Piotroski F Score | 7 | Strong | View |
| Beneish M Score | (2.50) | Unlikely Manipulator | View |
Haemonetics Debt to Cash Allocation
Many companies such as Haemonetics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Haemonetics has 1.22 B in debt with debt to equity (D/E) ratio of 1.12, which is OK given its current industry classification. Haemonetics has a current ratio of 2.68, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Haemonetics to invest in growth at high rates of return. Haemonetics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Haemonetics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Haemonetics, which in turn will lower the firm's financial flexibility.Haemonetics Corporate Bonds Issued
Most Haemonetics bonds can be classified according to their maturity, which is the date when Haemonetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Haemonetics Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Haemonetics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Haemonetics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Haemonetics. By using and applying Haemonetics Stock analysis, traders can create a robust methodology for identifying Haemonetics entry and exit points for their positions.
Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 2821 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Haemonetics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges |